INTRODUCTION
Antibodies have contributed considerably to our understanding ofthe molecular biology ofdiseases associated with abnormalities of Factor VIII Received for publication 20 August 1975 and in revised form 22 December 1976. 'Abbreviations used in this paper: VIII, activity, Factor VIII procoagulant activity; VIII antigen, Antigen which interacts with human antibody to Factor VIII (anti-VIII,) as shown by its ability to block the VIII, inactivating capacity of human anti-VIII antibodies. Heterologous antibodies directed against these antigens will also inactivate VIII activity; von Willebrand's disease antigen (Factor VIII-related antigen; vWAM), An antigen which precipitates with heterologous antibodies and which is decreased or absent in the plasma of most individuals with von Willebrand's disease. Though it co-purifies with VIII activity and VIII antigen under most conditions, its precise relationship to the molecule(s) expressing VIII, activity and/or VIII, antigen is a subject of considerable debate at present (11) (12) (13) (14) .
classic hemophilia but is either decreased or virtually absent in most cases of von Willebrand's disease (1, 2) . Human anti-VIII, antibody has also been used to explore the nature of the molecular defect in hemophilia. Human (11, 15) . After absorption the antiserum gave only one precipitin line against cryoprecipitates of normal plasma, but did not precipitate with concentrates of plasmas from individuals with severe von Willebrand's disease. Immobilized antibody was prepared by coupling ammonium sulfate precipitated globulin fractions of this antiserum (15) to Sepharose 2B agarose beads (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) with cyanogen bromide as described by others (16a). These beads removed both vWAM and VIIIC activity from normal plasma but not in a stoichiometric or 1:1 ratio (11) . Control beads were prepared by similarly coupling the globulin fractions of a pool of three nonnal rabbit sera to Sepharose 2B beads.
Preparation of normal human vWA antigen free of VIII, activity. Plasma (acid citrate dextrose or citrate phosphate dextrose) was initially absorbed with aluminum hydroxide (Rehsorptar, Armour Pharmaceuticals Co., Chicago, Ill.) by mixing 1 ml of aluminum hydroxide to 10 ml of plasma and stirring for 15 min at 22-25°C, and then removing the aluminum hydroxide by centrifugation at 15,826 g for 10 min. 1 vol of absorbed plasma was mixed for 1 h with 10 vol of packed QAE-Sephadex (G-50) which had been equilibrated with 0.01 M phosphate buffer, pH 7.2, adjusted to a conductance of 10 mmho with sodium chloride. The QAE-Sephadex was sedimented at 2,500 g for 10 min and washed twice in 10 times the volume of buffer with a conductance of 20 mmho.
VIII, and vWAg were eluted from the beads by two successive washes with a volume of buffer equal to that of the QAESephadex and with a conductance of 35 Removal of VIII, antigen and VWAU from hemophilic plasmas by heterologous antibody beads. Hemophilic plasmas with vWM concentrations greater than 1.5 U/ml were incubated with an equal vol (0.4 ml) of packed antibody beads, or control beads, for 4 h at 22-25°C with gentle rocking. The beads were removed by centrifugation at 7,000 g for 5 min in a Fisher centrifuge (Fisher Scientific Co., Pittsburgh, Pa.) and an equal volume of beads added to the supematant plasma as before and incubated overnight with gentle rocking. The beads were again removed by centrifugation. Less than 0.03 vWA, U/ml remained in the plasma after treatment by antibody beads. vWA concentrations in the same plasmas treated with control beads were decreased 20-40% but were still greater than 1.0 U/ml (Table V) . In some of the experiments VIII,-free vWAg isolated from normal plasma was then added to depleted hemophilic plasma to restore the vWAg content.
Assays of vWA, and VIII, activity. vWA was measured by a quantitative immunoelectrophoretic technique (15) . 1 U of vWA was defined as that amount present in 1 ml of a pool of plasma from 20 normal individuals (15) . VIII, activity was determined by a partial thromboplastin time technique with plasma from individuals with severe hemophilia A (less than 1% VIIIL) as substrate (17) .
Human antibodies to VIII,. Two antibodies were used.
One had developed in a nonhemophilic woman; the other in a severe classic hemophiliac. For most experiments, the antibodies were not isolated from the plasma before use, though they were diluted 20-fold or more in barbital buffered saline (2.76 g diethyl barbituric acid, 7.3 g sodium chloride, and 2.07 g sodium barbital/liter, pH 7.4-7.6).
Neither antibody plasma contained detectable VIII, and at the dilution used contained less than 0.05 U/vWAM. The first antibody was also used after it had been heated to 560C for 60 min and isolated from plasma by ammonium sulfate precipitation (15) . The hemophilic and nonhemophilic antibody preparations were used at sufficient dilution so that they introduced less than 5 or 0.5% respectively, of total vWA to the incubation mixtures. Neither antibody inactivated ristocetin cofactor activity.
Blocking assay for VIII, antigens with human anti-VIII, Hemophilic plasmas were from unrelated donors and contained less than 1% VIII,. All were obtained at least 2 wk after Factor VIII concentrate infusion and in some this interval was considerably greater (Table III) .
Blocking step. One part of blocking material (either hemophilic plasma, hemophilic plasma depleted of VWAg by rabbit antibody beads, VIII,-free vWAM prepared from normal plasma, or buffer as a control) was mixed with one part of human anti-VIII,. The anti-VIII,, which had been diluted to approximately 0.75 U/ml (3) so that it would inactivate only about 75-80% of the active VIIIC, was supplied in the second step curves. Hemophilic plasmas used in these experiments were obtained at least 2 wk after the last infusion of Factor VIII concentrate. The plasma samples from subjects no. 15 and 16 were tested after incubation with the globulin fraction of normal rabbit sera coupled to agarose beads (see Table V ). Tables) .
RESULTS
Each of the 16 hemophilic plasmas tested blocked the capacity ofnonhemophilic human anti-VIIIc antibody to inactivate VIIIc of normal plasma (Table I) . Three of these plasmas were also tested with human antibody which had arisen in a hemophiliac and similar results were obtained (Table II) . All of the plasmas tested were obtained at least 2 wk after the last infusion of Factor VIII concentrate. However, some were obtained after infusion-free periods of up to 79 days. Based on the t-Y2 of 20-40 h of vWAg observed by Bennett and Ratnoff (18) less than 5.4 x 10-13% of the material infused would have been remaining after this time. Yet, no significant difference in blocking by plasmas obtained after these prolonged infusionfree periods was seen as compared to plasmas obtained after much shorter infusion-free periods (Table III) . Thus, it is unlikely that infused Factor VIII can account for the blocking. Antibody separated from plasma by ammonium sulfate precipitation gave results similar to those obtained when antibody in diluted plasma was used (Table IV) . Blocking in this system is determined by assaying the VIII, activity remaining at the end of the indicator step incubation. IfVIIIc antigen is present in the blocking step then less antibody is free to inactivate the VIII, of the pooled normal plasma supplied in the indicator step. This is reflected as a shortened clotting Blocking of these two different preparations of the same antibody was assessed as for Table I . Hemophilic plasmas were depleted of VWAg by incubation with rabbit anti-VIII,-anti-vWAg which had been coupled to agarose beads (see Methods). As a control, the hemophilic plasma was incubated with the globulin fraction of normal rabbit serum which had been similarly coupled to agarose beads. vWg concentration indicated is that after incubation with control or antibody beads. The ability ofthese plasmas to block human nonhemophilic anti-VIII, was then evaluated as for Table I. time in the VIII, partial thromboplastin time assay.
To rule out nonspecific clotting time shortening due to the relatively concentrated hemophilic plasma used in the first step (hemophilic plasma:normal plasma pool ratio = 7.5:1) three additional experiments were performed. First, hemophilic plasma was incubated with immobilized rabbit antibody to VWAg and VIIIc (Table V) . This removed most of the vWAg (residual concentrations less than 0.03 U/ml). The capacity of the hemophilic plasma to block human anti-VIII, was also removed. However, nonimmune immobilized rabbit globulin did not remove the capacity of these same hemophilic plasmas to block.
Thus the shortened clotting time in the VIII, assay of the indicator step is directly related to material removed by the rabbit antibody and not to a nonspecific quality of the hemophilic plasma used for blocking. In addition, repletion of the hemophilic plasma with vWAg isolated from normal human plasmabut rendered free of VIII, activity-restored the ability of the vWAg depleted hemophilic plasma to block the human antibody (Figs. 1 and 2 ). This antigenic material blocked the human antibody comparably to hemophilic plasmas containing similar amounts ofvWAg. Secondly, the hemophilic plasmas to be tested were mixed with an equal amount of buffer instead of antibody, incubated for 2 h, then incubated for 2 h with an equal volume of buffer instead of diluted plasma pool. This mixture was then assayed in the partial thromboplastin time VIII, assay to see if the hemophilic plasmas alone could shorten the clotting time of the substrate plasma and thus give a false impression of blocking. Most hemophilic plasma tested had no effect on the assay clotting time as compared to that seen when buffer alone was assayed. Some plasmas lengthened the clotting time up to 5-8 s. An occasional plasma shortened the clotting time up to 5 s. Shortening of 5 s in this portion of the VIII, calibration curve amounted to less than 0.01 U/ml VIII, activity.
Though this was considerably less than the average of0.37 U/ml increase in VIII, activity seen in the blocking experiments, these plasmas were nevertheless excluded from the study.
Thirdly, hemophilic plasma was mixed with an equal volume of antibody, incubated 2 h, and then mixed with an equal volume of buffer instead of diluted normal plasma. This mixture was then incubated an additional 2 h and assayed in the partial thromboplastin time assay. The clotting time was unchanged for that seen when buffer alone was assayed in the partial thromboplastin time assay.
The reproducibility of the blocking assay was assessed by re-assaying samples of plasma from patient no. 10 on eight occasions over a 2-mo period. concentrations of antibody greater than 2.0 U/ml (3).
At concentrations of antibody less than this VIII, antigens were detected only in a minority of plasmas. In the studies reported here, however, antibody concentrations of 0.75 U/ml were effective in this regard.
The reason for the differences between the previously reported work and our study may reflect modifications we have introduced into the assay procedure. In These findings have implications for the molecular nature of the abnormality giving rise to hemophilia A as well as to the development of anti-VIII, antibodies in individuals with this disease. They suggest that antigenic differences between normal VIII, and the form of VIII, present in hemophilic plasma may be less marked than previously supposed. The presence of these VIII, antigens in all severe hemophiliacs tested may explain the relatively low incidence (8-14%) (20) of anti-VIII, antibodies developing in these individuals in spite of repeated transfusion therapy with active Factor VIII preparations.
